ArticleCureus2024
Decadal Trends and Associated Factors of Colorectal Cancer in Kerala Between 2010 and 2021 Among Patients in a Tertiary Hospital-Based Cancer Registry.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- MiR-3928 functions as a tumor suppressor and prognostic factor in colorectal cancer.Discover oncology · 2026Article
- Enhanced colorectal gland segmentation through multi-scale attention and contextual feature fusion.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction The incidence of colorectal cancer (CRC) has notably risen on a global scale, owing to modifications in lifestyle patterns and the overconsumption of processed food to meet nutritional requirements. Colorectal cancer is among the most common cancers in India, with a significant number of new cases reported annually. The aim of our study is to examine the trends and association of CRC in Kerala between the years 2010-2021 among patients reporting at a tertiary Hospital-Based Cancer Registry (HBCR) in Ernakulam. Methods A secondary data analysis was done using the data of CRC obtained from HBCR at Amrita Institute of Medical Sciences (AIMS), Kochi. All the reported patients diagnosed with CRC between the years 2010 and 2021 and residing in Kerala were included in the study. A total of 2,995 patients were included in the analysis. Results CRC cases rose until 2016 and then slightly decreased. However, joinpoint regression analysis showed a consistent rate of 0.1 cases per year, with no significant increase. Adenocarcinoma emerged as a histological subtype, and the highest number of CRC cases was reported in the year 2018; the prevailing and lowest was reported in the year 2020. Age and sex showed statistically significant associations with the histology of CRC. Furthermore, associations were also seen between the site of the lesion and the age of the patient. Conclusion The trends of CRCs showed that the cases were stable at a rate of 0.1 per year, and there was no significant increase. Robust cancer registries are required to continuously monitor CRC trends and outcomes, facilitating evidence-based decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.